Loading clinical trials...
Loading clinical trials...
Constitutive IL7 (C7R) Modified EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
Conditions
Interventions
Dose Level 1A: 2 x 10^7 cells/m2
Dose Level 2A: 6 x 10^7 cells/m2
+3 more
Locations
2
United States
Houston Methodist Hospital
Houston, Texas, United States
Texas Children's Hospital
Houston, Texas, United States
Start Date
October 31, 2022
Primary Completion Date
April 1, 2026
Completion Date
March 30, 2039
Last Updated
December 12, 2025
Lead Sponsor
Baylor College of Medicine
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions